As ubiquitous compounds in animals, bile acids (BAs) exert versatile biological activities far beyond lipid-absorption assistance. BAs have various chemical compositions (over 100 compounds), profound impacts on health and disease, and bidirectional regulation on both host and microbiota. Emerging evidence has indicated that BA profiles mediate the host-microbe mutual interactions through FXR/FGF15/FGFR4-triggered liver-gut feedback and FXR- and TGR5-induced BA metabolism. BA synthesis is governed by host homeostasis, and compositional alterations of BAs inversely reshaped the gut microbiota structure. Increasing efforts have been paid to develop BA-targeting drugs for preventing metabolic diseases including obesity, diabetes, hyperlipidemia, and hypertension. However, the molecular mechanism of BA metabolism and BA signaling during the onset and progress of metabolic diseases remains to be clarified. And the BA-targeting drugs or remedies should be extensively studied for hundreds of millions of potential patients.
BA metabolism and signaling build an intricate network that links commensal gut microbiota to host energy metabolism. Those BAs with different hydrophobicity and molecular configuration exhibit varied significance in obesity, diabetes, fatty liver diseases, and other metabolic diseases. It should be deeply investigated how this intricate network is established by various bile acids. How supplemented BAs benefit or hamper the alleviation of metabolic diseases? What is the molecular mechanism that BA-induced signaling acts on glucolipid metabolism?
Numerous oral drugs or natural products prevent chronic metabolic diseases through the regulation of gut microbiota. Increasing evidence has indicated that chemicals derived from traditional Chinese medicine prevented diseases through BA-induced signaling and metabolic regulation, such as berberine, dihydromyricetin, and curcumin. However, the impact of most active molecules on BA metabolism and BA signaling still remains elusive. Whether BA metabolism is the target for those orally administered active molecules?
This Research Topic will focus on BA-associated mechanism study and pharmacological research for metabolic diseases. The Research Topic welcomes Original Research and Insightful Reviews. This Topic will not consider merely descriptive study or pharmacological research without clear chemical composition. The scope covers the following contents (not limited).
• Contribution to the molecular mechanism of BA-mediated gut-liver interaction.
• Comparison and explanation of different bile acids in the same metabolic disease model.
• Revealing the role of BA metabolism or BA signaling in the pharmacological functions.
• Studying TCM extracts or dietary compounds by the gut microbiome and BA-targeted metabolomics.
• BA target identification for improving metabolic diseases including obesity, fatty liver diseases, hyperglycemia, hyperlipidemia, hypertension, and hyperuricemia.
As ubiquitous compounds in animals, bile acids (BAs) exert versatile biological activities far beyond lipid-absorption assistance. BAs have various chemical compositions (over 100 compounds), profound impacts on health and disease, and bidirectional regulation on both host and microbiota. Emerging evidence has indicated that BA profiles mediate the host-microbe mutual interactions through FXR/FGF15/FGFR4-triggered liver-gut feedback and FXR- and TGR5-induced BA metabolism. BA synthesis is governed by host homeostasis, and compositional alterations of BAs inversely reshaped the gut microbiota structure. Increasing efforts have been paid to develop BA-targeting drugs for preventing metabolic diseases including obesity, diabetes, hyperlipidemia, and hypertension. However, the molecular mechanism of BA metabolism and BA signaling during the onset and progress of metabolic diseases remains to be clarified. And the BA-targeting drugs or remedies should be extensively studied for hundreds of millions of potential patients.
BA metabolism and signaling build an intricate network that links commensal gut microbiota to host energy metabolism. Those BAs with different hydrophobicity and molecular configuration exhibit varied significance in obesity, diabetes, fatty liver diseases, and other metabolic diseases. It should be deeply investigated how this intricate network is established by various bile acids. How supplemented BAs benefit or hamper the alleviation of metabolic diseases? What is the molecular mechanism that BA-induced signaling acts on glucolipid metabolism?
Numerous oral drugs or natural products prevent chronic metabolic diseases through the regulation of gut microbiota. Increasing evidence has indicated that chemicals derived from traditional Chinese medicine prevented diseases through BA-induced signaling and metabolic regulation, such as berberine, dihydromyricetin, and curcumin. However, the impact of most active molecules on BA metabolism and BA signaling still remains elusive. Whether BA metabolism is the target for those orally administered active molecules?
This Research Topic will focus on BA-associated mechanism study and pharmacological research for metabolic diseases. The Research Topic welcomes Original Research and Insightful Reviews. This Topic will not consider merely descriptive study or pharmacological research without clear chemical composition. The scope covers the following contents (not limited).
• Contribution to the molecular mechanism of BA-mediated gut-liver interaction.
• Comparison and explanation of different bile acids in the same metabolic disease model.
• Revealing the role of BA metabolism or BA signaling in the pharmacological functions.
• Studying TCM extracts or dietary compounds by the gut microbiome and BA-targeted metabolomics.
• BA target identification for improving metabolic diseases including obesity, fatty liver diseases, hyperglycemia, hyperlipidemia, hypertension, and hyperuricemia.
